Get the Stockscreener App
47.47
1.69%
0.79
Exact Sciences Corp stock is traded at $47.47, with a volume of 2.02M.
It is up +1.69% in the last 24 hours and down -4.74% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$46.68
Open:
$46.96
24h Volume:
2.02M
Relative Volume:
0.65
Market Cap:
$8.99B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-8.6152
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
+4.10%
1M Performance:
-4.74%
6M Performance:
-3.63%
1Y Performance:
-19.62%
1-Day Range:
$46.57
$47.86
1-Week Range:
$44.80
$47.86
52-Week Range:
$38.81
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
47.47 | 8.54B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Volume spikes in Exact Sciences Corporation stock – what they meanTreasury Yields & AI Forecasted Stock Moves - Newser
Exact Sciences to Participate in September Investor Conferences - The Globe and Mail
What’s next for Exact Sciences Corporation stock priceTrade Exit Summary & Weekly High Potential Alerts - Newser
Analyzing Exact Sciences Corporation with risk reward ratio chartsWeekly Trading Summary & Expert Verified Movement Alerts - Newser
What earnings revisions data tells us about Exact Sciences CorporationJuly 2025 Action & High Accuracy Trade Signal Alerts - Newser
Published on: 2025-08-18 05:13:50 - Newser
5 Stocks with the Largest Fair Value Estimate Cuts After Q2 Earnings - Morningstar
Using flow based indicators on Exact Sciences Corporation2025 Dividend Review & Entry Point Confirmation Signals - Newser
Combining price and volume data for Exact Sciences CorporationWeekly Profit Summary & AI Powered Trade Plan Recommendations - Newser
Comparing Exact Sciences Corporation in custom built stock radarsWeekly Trade Review & High Win Rate Trade Alerts - Newser
Can Exact Sciences Corporation recover in the next quarterMarket Movers & Weekly Consistent Profit Watchlists - Newser
Cathie Wood’s ARK ETFs make major buys in Deere & Co, Exact Sciences stock - Investing.com Australia
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know - Yahoo Finance
EXAS Stocks Soar Amid Positive Trend: What’s Next? - StocksToTrade
Exact Sciences Corporation shares rise 6.70% intraday after Oracle's AI-driven EHR launch and Cadence's AI design advancements. - AInvest
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up - NewsBreak: Local News & Alerts
Piper Sandler Lowers Exact Sciences (NASDAQ:EXAS) Price Target to $60.00 - Defense World
Healthcare Analysts Weigh In on Immunocore Holdings and Exact Sciences - AInvest
The Top 5 Analyst Questions From Exact Sciences’s Q2 Earnings Call - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Price Target Cut to $60.00 by Analysts at BTIG Research - Defense World
What makes Exact Sciences Corporation stock price move sharplyFree Real Time Alerts Based on AI Prediction - Newser
BTIG Lowers Exact Sciences Price Target to $60, Maintains Buy Rating - AInvest
Exact Sciences price target lowered to $60 from $65 at BTIG - TipRanks
BTIG lowers Exact Sciences stock price target to $60 on Freenome deal - Investing.com Nigeria
Cathie Wood's Latest Buys: The Trade Desk, Pinterest, and Exact Sciences - AInvest
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution - Yahoo Finance
Key resistance and support levels for Exact Sciences CorporationReal-Time AI Sentiment and Price Forecast - Newser
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Here's Why Exact Sciences (EXAS) is a Strong Growth Stock - Yahoo Finance
Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 - Yahoo Finance
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
FY2025 EPS Forecast for Exact Sciences Increased by Analyst - Defense World
Applying Elliott Wave Theory to Exact Sciences CorporationEarnings Impact and Stock Reaction Analysis - Newser
How to read the order book for Exact Sciences CorporationFree Real Time Alerts Based on AI Prediction - Newser
Evercore ISI Group Lowers Price Target for Exact Sciences (EXAS) to $64 - AInvest
Real time social sentiment graph for Exact Sciences CorporationAI Entry Timing Prediction for Swing Traders - Newser
Real time scanner hits for Exact Sciences Corporation explainedTrading Volume Anomaly Summary and Insight - Newser
Cathie Wood Buys Alphabet, Exact Sciences Amid Market Volatility - WebProNews
Avantax Advisory Services Inc. Acquires 1,259 Shares of Exact Sciences Corporation (NASDAQ:EXAS) - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Exact Sciences - Defense World
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $60 to $70 - 富途牛牛
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Call Transcript - Insider Monkey
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock By Investing.com - Investing.com Australia
Cathie Wood’s ARK bolsters Exact Sciences, sheds DraftKings stock - Investing.com
Exact Sciences (NASDAQ:EXAS) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Exact Sciences 2025 Q2 Earnings Narrowed Losses and Raised Guidance - AInvest
Exact Sciences Corp’s Strong Earnings Call Highlights - TipRanks
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst - AOL.com
Is Exact Sciences, Down 8%, 'Throwing Good Money At Bad' In Its New Licensing Deal? - Investor's Business Daily
Why Is Exact Sciences Stock Tumbling Thursday?Exact Sciences (NASDAQ:EXAS) - Benzinga
Exact Sciences Earnings: Blood-Based Test Misses Cutoff for Medicare Reimbursement - Morningstar
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):